India, March 27 -- Dermata Therapeutics, Inc. (DRMA) Thursday reported positive topline results from the pivotal Phase 3 STAR-1 study of the company's lead product candidate Xyngari for the treatment of acne. The study met its primary goals. The company's shares were nearly 50 percent up in pre-market.
The STAR-1 study evaluated the efficacy, safety, and tolerability of Xyngari in patients with moderate-to-severe facial acne. Xyngari showed highly statistically significant and clinically meaningful improvement in acne in the study. Further, the drug candidate was appeared to be safe and well tolerated by patients with no serious adverse events.
The company plans to initiate a Phase 3 STAR-2 study in the second half of this year.
googleta...